Health care startups that raised Series A in Switzerland
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Rivia | Zürich | Series A | $15.0M | 2026-03-18 |
| Leman Biotech | Lausanne | Series A | $28.8M | 2026-01-26 |
| Comphya | Lausanne | Series A | $4.0M | 2025-07-08 |
| Odne | Dubendorf | Series A | $5.2M | 2025-06-12 |
| Rhygaze | Basel | Series A | $86.0M | 2025-01-10 |
| Lyfegen | Basel | Series A | $5.7M | 2024-12-11 |
| Vandria | Lausanne | Series A | $10.1M | 2024-08-21 |
| Neurosterix | Geneva | Series A | $65.0M | 2024-04-03 |
8 rows of the CSV in 5 of its 18 columns.
- The 89 health care startups in Switzerland whose last round is Series A have raised $1.0B in total.
- 5 of them closed their most recent round in the last 12 months, $60.8M combined.
- The largest of those rounds is Leman Biotech's $28.8M Series A, dated January 2026.
- The most recent is Neurogyn Ag's $4.8M Series A on 13 October 2026.
- Venture Kick is an investor in 12 of them, more than any other fund.
- Biotech is the most common other sector, with 47 companies (53%).
- 18% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (50% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
28 of 89| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Rivia | Rivia provides an operating system that aims to improve clinical trial outcomes. | Artificial intelligence | Zürich | Series A | $15.0M | 2026-03-18 | $18.2M | Speedinvest, Nina Capital, Amino Collective | 1 to 10 | 2022 |
| Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| Comphya | Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. | Biotech | Lausanne | Series A | $4.0M | 2025-07-08 | $14.2M | Venture Kick, Verve Ventures, Nest Collective Foundation | 1 to 10 | 2017 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Basel | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| Lyfegen | Lyfegen provides SaaS rebate management software for the healthcare industry. | Fintech | Basel | Series A | $5.7M | 2024-12-11 | MassChallenge, Innosuisse, APEX Ventures +1 | 51 to 100 | 2018 | |
| Vandria | Vandria creates mitophagy inducers that renew cells to address ageing and chronic disorders. | Health care | Lausanne | Series A | $10.1M | 2024-08-21 | Innosuisse, Dolby Family Ventures, Eurostars +1 | 1 to 10 | 2021 | |
| Neurosterix | Neurosterix is a biopharmaceutical firm creating allosteric modulators for neurological illnesses. | Biotech | Geneva | Series A | $65.0M | 2024-04-03 | $65.0M | Perceptive Advisors, Xontogeny, Acorn Bioventures | 11 to 50 | 2024 |
| Spirecut | Spirecut makes ultrasound-guided instruments that make minimally invasive surgery widely accessible. | Health care | Muttenz | Series A | $800K | 2024-03-26 | $2.2M | Innovate UK, MassChallenge Switzerland, Innosuisse +1 | 1 to 10 | 2020 |
| Scailyte | Scailyte delivers precision medicine through single-cell science. | Artificial intelligence | Basel | Series A | $1.8M | 2023-12-04 | $15.6M | Venture Kick, Verve Ventures, Innosuisse +2 | 11 to 50 | 2017 |
| mybacs | mybacs is a research-driven direct-to-consumer company specializing in the human microbiome. | Commerce | Zug | Series A | $5.9M | 2023-10-19 | Global Founders Capital, Social Starts, Joyance Partners +2 | 51 to 100 | 2019 | |
| TOLREMO therapeutics | TOLREMO therapeutics develops small molecules that target drug resistance pathways in cancer therapy. | Biotech | Zürich | Series A | $37.9M | 2023-09-20 | Altos Ventures, redalpine, BioMedPartners +1 | 11 to 50 | 2017 | |
| NewBiologix | NewBiologix is a technology innovation company. | Biotech | Epalinges | Series A | $50.3M | 2023-05-11 | $50.3M | Recipharm Venture Fund | 11 to 50 | 2023 |
| PeakData | PeakData provides a software platform that identifies and analyzes key opinion leaders in a therapeutic area. | Artificial intelligence | Zug | Series A | $12.4M | 2022-08-22 | Octopus Ventures, AlbionVC, Heal Capital | 51 to 100 | 2017 | |
| CDR-Life AG | CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. | Biotech | Schlieren | Series A | $76.0M | 2022-04-13 | $76.0M | RA Capital Management, Omega Funds, Jeito Capital | 51 to 100 | 2017 |
| Cimeio Therapeutics | Cimeio Therapeutics develops curative treatments for genetic diseases, blood cancers, and severe autoimmune disorders. | Biotech | Basel | Series A | $50.0M | 2022-04-13 | $50.0M | Versant Ventures | 11 to 50 | 2020 |
| Embion Technologies | Embion Technologies offers industrial biomass processing technology for nutrition, pharma, and cosmetics applications. | Biotech | Lausanne | Series A | $4.9M | 2021-12-08 | Venture Kick, Foundation for Innovation and Technology (FIT), Swiss Economic Award | 1 to 10 | 2016 | |
| Anjarium Biosciences | Anjarium Biosciences develops non-viral gene therapies to treat genetic diseases. | Biotech | Schlieren | Series A | $60.4M | 2021-09-15 | Gimv, Omega Funds, Pfizer Venture Investments +2 | 1 to 10 | 2017 | |
| Chord Therapeutics | Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases. | Biotech | Geneva | Series A | $16.0M | 2020-10-13 | Omega Funds, Eclosion SA | 1 to 10 | 2014 | |
| POLYNEURON | Polyneuron is a pharmaceutical company developing a new drug class for autoimmune disorders. | Biotech | Basel | Series A | $15.4M | 2020-09-16 | $45.0M | New Enterprise Associates, Venture Kick, Sofinnova Partners +1 | 1 to 10 | 2014 |
| yamo | Yamo sells food products for children directly to consumers. | Commerce | Zug | Series A | $11.4M | 2020-07-09 | b2venture, BackBone Ventures, Polytech Ventures +2 | 51 to 100 | 2016 | |
| Saphetor | Saphetor is a company that develops personalised medicine. | Biotech | Lausanne | Series A | $4.2M | 2020-03-27 | $6.6M | Foundation for Innovation and Technology (FIT), GoBeyond, Alpana Ventures +1 | 51 to 100 | 2014 |
| Inthera Bioscience | Inthera Bioscience develops inhibitors of intracellular protein interactions using a proprietary technology platform. | Biotech | Schlieren | Series A | $5.5M | 2018-06-26 | Microsoft Accelerator, Novo Holdings, M Ventures +2 | 11 to 50 | 2013 | |
| Intelligent Sensory concept | Intelligent Sensory concept is a biotechnology company that specializes in photomodulation. | Biotech | Geneva | Series A | $2.0M | 2018-05-18 | Rhône Finance | 11 to 50 | 2015 | |
| PIQUR Therapeutics | PIQUR Therapeutics is a Swiss pharmaceutical company developing anti-cancer drugs. | Biotech | Basel | Series A | $30.9M | 2017-09-01 | $86.9M | Venture Kick, Versant Ventures | 11 to 50 | 2011 |
| Pevion Biotech | Pevion Biotech is a biotechnology company that uses its proprietary technology platforms. | Biotech | Bern | Series A | $29.2M | 2007-08-13 | $29.2M | BB Biotech Ventures, BZ Bank | 11 to 50 | 2002 |
| 4-Antibody AG | 4-Antibody AG develops a human antibody drug-discovery platform for immuno-oncology therapeutics. | Biotech | Basel | Series A | $18.4M | 2007-01-16 | $20.6M | EQT Life Sciences, BioMedPartners, Grazia Equity +2 | 251 to 500 | 2002 |
| Moda Technology Partners | Moda Technology Partners develops commercial software. | Health care | Basel | Series A | $2.3M | 2006-07-11 | Osage Venture Partners | 11 to 50 | 2005 | |
| Roche Glycart | Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. | Biotech | Schlieren | Series A | $13.6M | 2003-11-26 | $13.6M | Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 | 101 to 250 | 2000 |
Table 1. Health care startups that raised Series A in Switzerland: the 28 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 89.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| 2 | Rivia | Rivia provides an operating system that aims to improve clinical trial outcomes. | Artificial intelligence | Zürich | Series A | $15.0M | 2026-03-18 | $18.2M | Speedinvest, Nina Capital, Amino Collective | 1 to 10 | 2022 |
Table 2. Health care startups that raised Series A in Switzerland: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Venture Kick | Startup incubator | Schlieren, Switzerland | 12 | 13% | ||
| 2 | Foundation for Innovation and Technology (FIT) | Entrepreneurship program | Lausanne, Switzerland | 5 | 6% | ||
| 3 | Innosuisse | Government investment office | Berne, Switzerland | 4 | 4% | ||
| 4 | Verve Ventures | Venture capital firm | Zug, Switzerland | 3 | 3% | ||
| 5 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 3 | 3% | ||
| 6 | BioMedPartners | Venture capital firm | Basel, Switzerland | 3 | 3% | ||
| 7 | Omega Funds | Secondary purchaser | Boston, United States | 3 | 3% | ||
| 8 | b2venture | Venture capital firm | Berlin, Germany | 2 | 2% | ||
| 9 | Versant Ventures | Venture capital firm | Menlo Park, United States | 2 | 2% | ||
| 10 | M Ventures | Corporate venture arm | Amsterdam, The Netherlands | 2 | 2% | ||
| 11 | Gilde Healthcare | Private equity firm | Utrecht, The Netherlands | 2 | 2% | ||
| 12 | Polytech Ventures | Micro VC fund | Lausanne, Switzerland | 2 | 2% | ||
| 13 | Amino Collective | Venture capital firm | Berlin, Germany | 1 | 1% | 1 | Rivia |
| 14 | Nina Capital | Micro VC fund | Barcelona, Spain | 1 | 1% | 1 | Rivia |
| 15 | Speedinvest | Venture capital firm | Vienna, Austria | 1 | 1% | 1 | Rivia |
Table 3. Health care startups that raised Series A in Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 47 | 53% | $744.4M |
| Software | 20 | 22% | $109.4M |
| Artificial intelligence | 11 | 12% | $67.6M |
| Hardware | 4 | 4% | $44.8M |
| Commerce | 4 | 4% | |
| Fintech | 1 | 1% | |
| Energy | 1 | 1% |
Table 4. Health care startups that raised Series A in Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 89 | 100% | $5.9M |
Table 5. Health care startups that raised Series A in Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Basel | 14 | 16% |
| Zürich | 13 | 15% |
| Lausanne | 13 | 15% |
| Epalinges | 6 | 7% |
| Schlieren | 6 | 7% |
| Geneva | 4 | 4% |
| Zug | 4 | 4% |
| Neuchâtel | 3 | 3% |
| Pfaffikon | 2 | 2% |
| Risch | 1 | 1% |
| Wallisellen | 1 | 1% |
| Dubendorf | 1 | 1% |
Table 6. Health care startups that raised Series A in Switzerland by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 20% | $4.8M |
| June 2026 | 1 | 20% | $5.3M |
| March 2026 | 2 | 40% | $22.0M |
| January 2026 | 1 | 20% | $28.8M |
Table 7. Health care startups that raised Series A in Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 5 | 6% | $60.8M |
| 2025 | 9 | 10% | $178.8M |
| 2024 | 13 | 15% | $159.0M |
| 2023 | 8 | 9% | $133.9M |
| 2022 | 5 | 6% | $181.4M |
| 2021 | 13 | 15% | $114.3M |
Table 8. Health care startups that raised Series A in Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 3% |
| 2020 to 2022 | 13 | 15% |
| 2015 to 2019 | 39 | 44% |
| 2010 to 2014 | 22 | 25% |
| Before 2010 | 12 | 13% |
Table 9. Health care startups that raised Series A in Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 27 | 31% |
| 11 to 50 | 44 | 50% |
| 51 to 100 | 13 | 15% |
| 101 to 250 | 3 | 3% |
| 251 to 500 | 1 | 1% |
Table 10. Health care startups that raised Series A in Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series A and its headquarters is in Switzerland. On 16 November 2026 that is 89 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 28 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 89 rows: 17 have no round amount, 0 no city and 30 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in Switzerland whose last round is Series A are on the list?
- 89, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 89 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.